# A Clinical Trial of Bomedemstat in Participants With Polycythemia Vera (MK-3543-025)

> **NCT07722611** · PHASE2,PHASE3 · RECRUITING · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 380 (estimated)

## Conditions studied

- Polycythemia Vera

## Interventions

- **DRUG:** Bomedemstat
- **DRUG:** Ruxolitinib
- **DRUG:** Ropeginterferon alfa-2b

## Key facts

- **NCT ID:** NCT07722611
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-10-07
- **Primary completion:** 2032-06-25
- **Final completion:** 2032-11-30
- **Target enrollment:** 380 (ESTIMATED)
- **Last updated:** 2026-09-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07722611

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07722611, "A Clinical Trial of Bomedemstat in Participants With Polycythemia Vera (MK-3543-025)". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07722611. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*